Cover Image
市場調查報告書

原發性硬化性膽管炎:開發平台分析

Primary Sclerosing Cholangitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246021
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
原發性硬化性膽管炎:開發平台分析 Primary Sclerosing Cholangitis - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 87 Pages
簡介

原發性硬化性膽管炎(PSC)是慢性的肝臟疾病,特徵是伴隨發炎的進行性膽汁滯留,及肝內·肝外的總肝膽管的纖維化等。主要的症狀有腹痛和發冷,腹瀉,倦怠感,發癢,體重減少等。主要的易罹病素質包含了年齡和發炎性腸道疾病等。此外主要治療方法有抗生素和抗組織胺藥物,膽汁酸粘合劑等。

本報告提供全球各國治療原發性硬化性膽管炎(PSC)所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

原發性硬化性膽管炎概要

治療藥的開發

  • 原發性硬化性膽管炎開發中產品:概要
  • 原發性硬化性膽管炎開發中產品:比較分析

企業正在開發的治療藥

開發中產品概況

  • 臨床階段的產品

企業開發中的產品

治療藥的開發企業

  • Biotie Therapies Corp.
  • ChemoCentryx, Inc.
  • Dr. Falk Pharma GmbH
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Shire Plc

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BTT-1023
  • CCX-507
  • norursodeoxycholic acid
  • obeticholic acid
  • SHP-625
  • simtuzumab

最新開發平台趨勢

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8237IDB

Summary

Global Markets Direct's, 'Primary Sclerosing Cholangitis - Pipeline Review, H2 2016', provides an overview of the Primary Sclerosing Cholangitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis
  • The report reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects
  • The report assesses Primary Sclerosing Cholangitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Primary Sclerosing Cholangitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Sclerosing Cholangitis Overview
  • Therapeutics Development
    • Pipeline Products for Primary Sclerosing Cholangitis - Overview
  • Primary Sclerosing Cholangitis - Therapeutics under Development by Companies
  • Primary Sclerosing Cholangitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Primary Sclerosing Cholangitis - Products under Development by Companies
  • Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
    • Biotie Therapies Corp.
    • ChemoCentryx, Inc.
    • Dr. Falk Pharma GmbH
    • Genextra S.p.a.
    • Gilead Sciences, Inc.
    • iCo Therapeutics Inc.
    • NGM Biopharmaceuticals, Inc.
    • Sancilio & Company, Inc.
    • Shire Plc
    • Takeda Pharmaceutical Company Limited
    • TGV-Laboratories
    • Tobira Therapeutics, Inc.
  • Primary Sclerosing Cholangitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • bertilimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTT-1023 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenicriviroc mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hep-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • maralixibat chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • norursodeoxycholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-404 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • simtuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Primary Sclerosing Cholangitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vedolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Sclerosing Cholangitis - Dormant Projects
  • Primary Sclerosing Cholangitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2016: Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases
      • Apr 16, 2016: Investigational treatment provides hope for some chronic liver disease sufferers
      • Apr 16, 2016: Gilead Presents New Data on Simtuzumab at The International Liver Congress 2016
      • Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis
      • Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015
      • Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting
      • Mar 31, 2015: Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis
      • Feb 17, 2015: BTT1023 receives positive opinion for Orphan Drug Designation from COMP
      • Jul 24, 2014: Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding
      • Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
      • Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Primary Sclerosing Cholangitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by Biotie Therapies Corp., H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by ChemoCentryx, Inc., H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by Genextra S.p.a., H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences, Inc., H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by iCo Therapeutics Inc., H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company, Inc., H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by TGV-Laboratories, H2 2016
  • Primary Sclerosing Cholangitis - Pipeline by Tobira Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Primary Sclerosing Cholangitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Primary Sclerosing Cholangitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top